Summary
Overview
Work History
Education
Skills
PUBLICATIONS, PATENTS & APPLICATION NOTES
Timeline
Generic

Chloe Whitehouse

London

Summary

PhD-trained neuroscientist and Science and Technology Lead on ARIA’s £69m Precision Neurotechnologies programme. I use technical judgement to convert biological, hardware, software and clinical uncertainty into clear portfolio decisions. I am driven by shaping translational pathways, strengthening cross-sector partnerships and securing investment to advance promising projects. I actively apply evidence-led judgement to programme reviews, milestone setting and risk management.

Overview

5
5
years of professional experience

Work History

Science and Technology Lead

ARIA
02.2026 - Current
  • Advocated for more than £8M of seed-boost investment and accelerations across projects whose early results supported doubling down, defining the technical case, risks and milestone structure.
  • Stewarded ARIA's Precision Neurotechnologies portfolio, collaborating with Programme Director Jacques Carolan to evaluate technical evidence across biological, hardware, software and clinical milestones.
  • Transformed technical uncertainty and risk into actionable portfolio decisions through comprehensive technical reviews, quarterly assessments and site visits.
  • Developed translational pathways and fostered communities around emerging neurotechnologies, linking Creators with clinicians, regulators, investors, and activation partners.

Senior Specialist

Merck Sharp & Dohme UK Ltd
07.2024 - 12.2025
  • Led the creation and strategic direction of MSD's UK 3D Biofabrication Hub, establishing a new capability for human-relevant neurodegeneration modelling and expanding its use across multiple therapeutic programmes.
  • Designed and delivered next-generation 3D bioprinted models, demonstrating improved physiological relevance and enabling more predictive drug efficacy and biomarker studies.
  • Established and maintained collaborations across academia, biotech, and internal R&D to enhance access to cutting-edge tools, biomaterials, and platform technologies.
  • Collaborated with multidisciplinary teams in biology, engineering, and bioinformatics to achieve timely delivery of project milestones.
  • Developed and implemented technical risk assessments and SOPs, improving training and unifying scientific processes.
  • Authored technical reports and publications that effectively communicated inventions to internal and external stakeholders.

Postdoctoral Fellow

Merck Sharp & Dohme
09.2021 - 06.2024
  • Developed multicellular 3D neurodegeneration models integrating neurons, astrocytes, microglia, and oligodendrocyte precursors, improving recapitulation of human pathology.
  • Implemented new analytical pipelines (imaging, electrophysiology assays, molecular analyses) to quantify platform performance and drive model-disease alignment.
  • Optimised biomaterial formulations to enhance cell viability, maturation, and functional performance, contributing to improved model outcomes.
  • Presented complex, interdisciplinary results to cross-functional teams and senior stakeholders, facilitating strategic alignment and informed resource allocation.
  • Led international Merck Postdoctoral Network as president, organised two global symposia, and developed workflows to streamline onboarding for new postdocs.

PhD Researcher

University of Nottingham (in collaboration with Vertex Pharmaceuticals)
London
09.2021 - 06.2024
  • Engineered microphysiological 'blood-brain barrier on-a-chip' model, enhancing prediction of CNS pharmacokinetics for Vertex's drug development programmes.
  • Benchmarked model against existing in vitro systems, showcasing significant improvements in physiological relevance and analytical sensitivity.

Education

Diploma - Leadership and Management

Corndel
01-2026

Doctor of Philosophy - Pharmacology

University of Nottingham
01-2021

Bachelor of Science (Hons) - Neuroscience with Pharmacology

University of Nottingham
01-2017

Skills

  • Research roadmapping and experiment design
  • Scientific due diligence and proposal review
  • Technical mentoring and milestone reviews
  • Funding cases and portfolio decisions
  • Research translation strategy
  • Product requirements and evidence strategy
  • Scientific and translation partnerships
  • Interdisciplinary research and communication
  • Pitch decks and investor introductions
  • Founder coaching and customer discovery

PUBLICATIONS, PATENTS & APPLICATION NOTES

  • Whitehouse, C., Corbett, N., & Brownlees, J., 2023-01-01, 3D models of neurodegeneration: implementation in drug discovery., Trends in Pharmacological Sciences, 44, 4, 208-221 [review - cover article]
  • Whitehouse, C. A., He, Y., Brownlees, J., Corbett, N., 2023-01-01, Three-Dimensional Bioprinting of Human iPSC-Derived Neuron-Astrocyte Cocultures for Screening Applications., J. Vis. Exp., 199, e65856
  • Whitehouse, C., Bravington, E., Patir, A., Wei, W., Brownlees, J., He, Y., & Corbett, N., 2025-01-01, Investigating Connectivity Deficits in Alzheimer's Disease Using a Novel 3D Bioprinted Model Designed to Quantify Neurite Outgrowth., Bioengineering, 12, 3, 245
  • Whitehouse, C. A., Blood-Brain Barrier On-A-Chip Model for the Study of Drug Permeability Into the Brain. University of Nottingham (United Kingdom) ProQuest Dissertations & Theses, 2021. 30474818.
  • Patent: "Tri-matrix 3D bioprinted neurite outgrowth model" from Whitehouse, C., Bravington, E., Patir, A., Wei, W., Brownlees, J., He, Y., & Corbett, N., 2025-01-01, Investigating Connectivity Deficits in Alzheimer's Disease Using a Novel 3D Bioprinted Model Designed to Quantify Neurite Outgrowth., Bioengineering.
  • Application note: 3D Bioprinting of iPSC neuron-astrocyte cocultures [bit.bio] https://www.bit.bio/resources/publications/3d-bioprinting-of-ipsc-neuron-astrocyte-coculture
  • Application note: 3D Bioprinting of neural cocultures for screening [Invntia] https://invntia.life/resources/publication/s/three-dimensional-bioprinting-of-human-ipsc-derived-neuron-astrocyte-cocultures-for-screening-applications/

Timeline

Science and Technology Lead

ARIA
02.2026 - Current

Senior Specialist

Merck Sharp & Dohme UK Ltd
07.2024 - 12.2025

Postdoctoral Fellow

Merck Sharp & Dohme
09.2021 - 06.2024

PhD Researcher

University of Nottingham (in collaboration with Vertex Pharmaceuticals)
09.2021 - 06.2024

Diploma - Leadership and Management

Corndel

Doctor of Philosophy - Pharmacology

University of Nottingham

Bachelor of Science (Hons) - Neuroscience with Pharmacology

University of Nottingham
Chloe Whitehouse